Sanofi is expecting supply constraints of its infant RSV antibody Beyfortus, which it co-developed with AstraZeneca, in the first quarter of this year. While it is expecting to boost production, the company says it’s too early to say by how much.
The French pharma is working to lift any manufacturing bottlenecks and “unlock capacity” to tackle supply constraints, but “the question is how much progress we can make in 2024,” CEO Paul Hudson noted on a media call Thursday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.